Gerpevir
Relapsing-Remitting Multiple Sclerosis
Genzyme, a Sanofi CompanySmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
71 Active assets in the Relapsing-Remitting Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Glatiramer University Hospital, Montpellier | Phase 4 | BBB |
Natalizumab Biogen | Phase 4 | BBB |
Fingolimod TG Therapeutics, Inc. | Phase 4 | BBB |
Interferon ?1 (Human Fibroblast Protein Moiety) Biogen | Phase 4 | BBB |
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER University Hospital, Montpellier | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Gerpevir is also rated in:
disease related to hematopoietic stem cell transplantDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →